Covered recipient · General Payments record
JOHN R CHEREGI
Allopathic & Osteopathic Physicians Surgery
General Payments · PY2018–2024
$14,665.79
- Reported across 76 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $2,520.00 | 2 |
| Food and Beverage | $651.31 | 15 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Medtronic, Inc. | $2,879.89 | 7 |
| Novo Nordisk AS | $115.02 | 5 |
| BAXTER HEALTHCARE | $88.89 | 1 |
| CONMED Corporation | $41.67 | 1 |
| Currax Pharmaceuticals LLC | $30.16 | 2 |
| Lilly USA, LLC | $15.68 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (17)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Baxter Healthcare | $88.89 | 01/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1120532879 | CMS |
| CONMED Corporation | $41.67 | 01/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1142397123 | CMS |
| Currax Pharmaceuticals LLC | $13.93 | 01/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1089511854 | CMS |
| Currax Pharmaceuticals LLC | $16.23 | 04/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1089511856 | CMS |
| Lilly USA, LLC | $15.68 | 01/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135072301 | CMS |
| Medtronic, Inc. | $158.09 | 04/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1119472893 | CMS |
| Medtronic, Inc. | $1,260.00 | 08/05/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1112052603 | CMS |
| Medtronic, Inc. | $1,260.00 | 10/09/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1112052605 | CMS |
| Medtronic, Inc. | $78.45 | 10/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1119472895 | CMS |
| Medtronic, Inc. | $18.35 | 10/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1119472897 | CMS |
| Medtronic, Inc. | $88.90 | 10/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1119472899 | CMS |
| Medtronic, Inc. | $16.10 | 10/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1119472901 | CMS |
| Novo Nordisk Inc | $23.64 | 02/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096801164 | CMS |
| Novo Nordisk Inc | $23.33 | 04/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097397888 | CMS |
| Novo Nordisk Inc | $23.10 | 09/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097234996 | CMS |
| Novo Nordisk Inc | $24.27 | 10/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096956507 | CMS |
| Novo Nordisk Inc | $20.68 | 11/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096900549 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.